NO900155L - Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1. - Google Patents

Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.

Info

Publication number
NO900155L
NO900155L NO90900155A NO900155A NO900155L NO 900155 L NO900155 L NO 900155L NO 90900155 A NO90900155 A NO 90900155A NO 900155 A NO900155 A NO 900155A NO 900155 L NO900155 L NO 900155L
Authority
NO
Norway
Prior art keywords
sicam
icam
purified
different
relates
Prior art date
Application number
NO90900155A
Other languages
English (en)
Norwegian (no)
Other versions
NO900155D0 (no
Inventor
Jeffrey Greve
Alan Mcclelland
Original Assignee
Molecular Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26972210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO900155(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/301,192 external-priority patent/US5235049A/en
Application filed by Molecular Therapeutics Inc filed Critical Molecular Therapeutics Inc
Publication of NO900155D0 publication Critical patent/NO900155D0/no
Publication of NO900155L publication Critical patent/NO900155L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Bipolar Transistors (AREA)
NO90900155A 1989-01-24 1990-01-11 Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1. NO900155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/301,192 US5235049A (en) 1989-01-24 1989-01-24 Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
US44595189A 1989-12-13 1989-12-13

Publications (2)

Publication Number Publication Date
NO900155D0 NO900155D0 (no) 1990-01-11
NO900155L true NO900155L (no) 1990-07-25

Family

ID=26972210

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90900155A NO900155L (no) 1989-01-24 1990-01-11 Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.

Country Status (15)

Country Link
EP (1) EP0379904B1 (de)
JP (1) JP3080631B2 (de)
KR (1) KR100202435B1 (de)
AT (1) ATE137799T1 (de)
AU (1) AU641134B2 (de)
DE (1) DE69026844T2 (de)
DK (1) DK0379904T3 (de)
ES (1) ES2087091T3 (de)
FI (1) FI100601B (de)
GR (1) GR3020481T3 (de)
IE (1) IE74144B1 (de)
IL (1) IL93119A (de)
NO (1) NO900155L (de)
NZ (1) NZ232203A (de)
PT (1) PT92920B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
EP0362531B1 (de) * 1988-09-01 1999-11-10 Bayer Corporation Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
ES2177695T3 (es) * 1989-03-16 2002-12-16 Blood Res Center Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.
HU217792B (hu) * 1989-03-16 2000-04-28 Dana Farber Cancer Institute Eljárás intercelluláris adhéziós molekula (ICAM-1) oldható származékai és ezeket tartalmazó gyógyszerkészítmények előállítására
US6797270B1 (en) 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
DK0468257T3 (da) * 1990-07-20 2000-03-27 Bayer Ag Multimer form af human rhinovirusreceptorprotein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
AU710965B2 (en) * 1992-06-22 1999-09-30 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
FR2710778B1 (fr) * 1993-09-29 1995-12-01 Framatome Sa Grappe de commande pour réacteur nucléaire et réacteur en faisant application.
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US20020081294A1 (en) 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
CA2273195A1 (en) * 1997-10-02 1999-04-15 Icos Corporation Icam-4 and diagnostic uses thereof
FR2788161B1 (fr) * 1998-12-30 2001-03-23 Framatome Sa Crayon absorbant pour grappe de commande de reacteur nucleaire
ATE439145T1 (de) 1999-03-19 2009-08-15 Genentech Inc Behandlung von lfa-1 assozieerten krankheiten durch gesteigerte dosen von lfa-1 antagonist
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
EP1599602B1 (de) * 2003-02-14 2015-01-14 Beth Israel Deaconess Medical Center, Inc. Vorraussagen von abstossung
JP4671323B2 (ja) * 2004-04-28 2011-04-13 大日本印刷株式会社 ディスプレイ装置
WO2005123777A2 (en) 2004-06-09 2005-12-29 Genentech, Inc. Method of treating granuloma annulare or sarcoid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854536T2 (de) * 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
ES2064327T3 (es) * 1987-11-02 1995-02-01 Baylor College Medicine Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor
EP0362531B1 (de) * 1988-09-01 1999-11-10 Bayer Corporation Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
AU636230B2 (en) * 1990-10-24 1993-04-22 Dolores Y. Beaupied Garment to hold an ostomy appliance

Also Published As

Publication number Publication date
NO900155D0 (no) 1990-01-11
AU4876790A (en) 1990-08-02
JPH0381296A (ja) 1991-04-05
KR100202435B1 (ko) 1999-06-15
IL93119A (en) 1999-07-14
DE69026844T2 (de) 1996-09-12
IE74144B1 (en) 1997-07-02
JP3080631B2 (ja) 2000-08-28
EP0379904A1 (de) 1990-08-01
IE900257L (en) 1990-07-24
NZ232203A (en) 1992-10-28
PT92920A (pt) 1990-07-31
AU641134B2 (en) 1993-09-16
IL93119A0 (en) 1990-11-05
DK0379904T3 (da) 1996-09-16
EP0379904B1 (de) 1996-05-08
GR3020481T3 (en) 1996-10-31
FI100601B (fi) 1998-01-15
ATE137799T1 (de) 1996-05-15
DE69026844D1 (de) 1996-06-13
ES2087091T3 (es) 1996-07-16
FI900331A0 (fi) 1990-01-22
KR900011895A (ko) 1990-08-02
PT92920B (pt) 1995-12-29

Similar Documents

Publication Publication Date Title
NO900155D0 (no) Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2008368A1 (en) Soluble molecule related to but distinct from icam-1
ATE98376T1 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
DE69330372D1 (de) ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN
EP1035870A4 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
NZ520071A (en) 4-aminopiperidine derivatives and their use as medicine
IL142499A0 (en) Building units for synthesis of backbone cyclized peptide analogs
ES2101299T3 (es) Sustancia exenta de mitogenos, su preparacion y su uso.
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
TR200000015T2 (tr) Bileşikler ve metodlar
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
MX9702932A (es) L-ribofuranosilnucleosidos.
TR199900501T2 (xx) Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�.
ATE210147T1 (de) Glycokonjugate von modifizierten camptothecin- derivaten(a- oder b-ring-verknüpfung)
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
KR900002799A (ko) 뉴로펩티드 y 애고니스트
DE69804839D1 (de) Cd8 als inhibitor des zellulären immunsystems
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
FR2422720A2 (fr) Separation et purification de proteines par chromatographie
GR1000719B (el) Μεθοδος παρασκευης της (s)-α-εθυλ-2-οξο-1-πυρρολιδινοακεταμιδης.
ES2117664T3 (es) Carboximetilmanoglucanos y derivados de los mismos.
HUP0003174A2 (hu) 20(S)-Kamptotecin glikokonjugátumai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
Hofmann et al. Studies on Polypeptides. XII the Synthesis of a Physiologically Active Blocked Tridecapeptide Amide Possessing the Amino Acid Sequence of α-MSH1
KATZ et al. Synthesis, characterization and inhibitory activities of (4‐N3 [3, 5‐3H] Phe10) PKI (6–22) amide and its precursors: photoaffinity labeling peptides for the active site of cyclic AMP‐dependent protein kinase